GlassScriptPhysician profile
Rashida Stevenson
NPI 1326257080
$5,073.70
in general payments reported to CMS, 2019-2025
36 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $137 · 2021: $94.42 · 2022: $219 · 2023: $1,269 · 2024: $2,037 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,341 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,341.43 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $555.80 | 2024-2025 | |
| Lundbeck LLC | $550.00 | 2023-2025 | Vyepti, Rexulti |
| Pfizer INC. | $527.86 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $415.59 | 2023-2024 | Aptiom |
| Biogen, INC. | $399.45 | 2019-2024 | Tysabri, Vumerity, Avonex |
| Abbvie INC. | $262.84 | 2023-2025 | Qulipta |
| Neurelis, INC. | $214.96 | 2023-2025 | Valtoco |
| Genentech USA, INC. | $194.56 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $194.32 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Emd Serono, INC. | $167.29 | 2022-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $166.44 | 2019-2024 | Ultomiris |
| Ucb, INC. | $162.51 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Eisai INC. | $151.65 | 2020-2025 | |
| Sk Life Science, INC. | $137.88 | 2023-2025 | |
| Lilly USA, LLC | $102.56 | 2024 | Emgality, Reyvow |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $91.12 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.25 | 2024-2025 | Hyqvia |
| Nevro Corp. | $74.98 | 2023-2024 | Senza |
| Jazz Pharmaceuticals INC. | $63.39 | 2024 | |
| Grifols USA, LLC | $61.24 | 2024-2025 | Gamunex-C |
| Catalyst Pharmaceuticals, INC. | $59.10 | 2023-2024 | Fycompa |
| Genzyme Corporation | $51.03 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $46.06 | 2024 | Rexulti |
| Tanabe Pharma America, INC. | $42.15 | 2024-2025 | Radicava |
| Amgen INC. | $41.67 | 2024 | Uplizna |
| Acadia Pharmaceuticals INC | $40.38 | 2023-2025 | Nuplazid |
| Alnylam Pharmaceuticals INC. | $37.20 | 2023 | Onpattro |
| Medtronic, INC. | $31.76 | 2023 | Percept PC Brainsense |
| Harmony Biosciences LLC | $29.22 | 2025 | |
| Argenx US, INC. | $23.18 | 2024 | Vyvgart Hytrulo |
| Livanova USA, INC. | $21.01 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Mallinckrodt Hospital Products INC. | $20.35 | 2024 | Acthar |
| Collegium Pharmaceutical, INC. | $18.76 | 2022 | |
| Currax Pharmaceuticals LLC | $14.84 | 2024 | Contrave, Onzetra Xsail |
| Almatica Pharma LLC | $13.97 | 2023 | Gralise |
| Medtronic USA, INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashida Stevenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.